As previously reported, Canaccord analyst Tania Armstrong-Whitworth downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a price target of C$6.50, down from C$7.25, after having incorporated Q4 results, 2025 guidance and a half-year contribution from Paladin in the firm’s forecasts. The firm is downgrading given the recent jump in share price post-Paladin deal announcement and “resultant minimal upside from current levels,” the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Reports Record-High Revenues in 2024
- Knight Therapeutics downgraded to Hold from Buy at Canaccord
- Knight Therapeutics Achieves Record Revenues and Expands Product Approvals
- Knight Therapeutics reports FY24 EPS C$0.04 vs. (C$0.16) last year
- Knight Therapeutics sees FY25 revenue C$390M-C$405M
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue